This video is sponsored by the Duke Clinical Medical Series.
Topics include:
* Role of Adjunctive Abciximab Prior to PCI in ACS Pts Pretreated with Clopidogrel:
ISAR-REACT-2
* ISAR-REACT 2
* Gp IIb/IIIa in PCI
* EPIC Trial: Long-term FU
* PCI in Gp IIb/IIIa Trials UA/NSTEMI Population
* Baseline Tn, Gp IIb/IIIa, & Outcomes in ACS
* ISAR-REACT 2
* Nonrandomized Data: Thienopyridine Pretreatment
* Benefit of Clopidogrel Pretreatment with PCI
* ISAR-REACT
The moderator, Peter Berger, MD, has indicated that he receives research/grant support
from Aventis, Conor, Guilford, Lumen, and Velocimed. Dr. Berger is also a member of an
advisory board for Genentech and Cordis/Johnson & Johnson; he has spoken at scientific
symposia for Aventis, Bristol-Myers Squibb, Genentech, and Guilford. Dr. Berger also
serves as Medical Director and has equity with Lumen, Inc.
The guest faculty, Dr. Steven Steinhubl, has indicated that he received research/grant
support, and is a consultant for, The sanofi-aventis Group and The Medicine's Company.
n/a
|
|